INTRODUCTION
============

Acute cholecystitis is one of the most common biliary diseases and sometimes presents as an emergency condition, possibly inducing severe complications when appropriate drainage is not carried out. Therefore, gallbladder drainage at an early stage is essential in patients with severe cholecystitis if multiple organ dysfunction or severe local inflammation is found \[[@b1-ce-2019-177]\]. Cholecystectomy remains the gold standard management approach for patients with acute cholecystitis. Since the introduction of laparoscopic cholecystectomy (LC), minimally invasive surgery has been commonly performed in patients with acute cholecystitis, compared with open cholecystectomy (OC) \[[@b2-ce-2019-177]\]. However, these surgical procedures may result in increased mortality in elderly patients and/or in those with multiple severe comorbidities \[[@b3-ce-2019-177]\]. In such cases, percutaneous transhepatic gallbladder drainage (PTGBD) is often performed instead of surgery. PTGBD is an effective clinical method of primary drainage with a high technical success rate \[[@b4-ce-2019-177]\]. However, PTGBD is generally prohibited in patients with massive ascites, anatomically inaccessible gallbladders, and a high risk of self-removal of the drainage tube, and it is especially risky in patients with a bleeding tendency \[[@b5-ce-2019-177]\]. In addition, PTGBD is associated with adverse events including bleeding or bile leakage, a high recurrence rate, and fistula formation after longterm stent placement and stent displacement \[[@b4-ce-2019-177],[@b5-ce-2019-177]\].

Considering these disadvantages, endoscopic gallbladder drainage (EGBD), including endoscopic transpapillary gallbladder drainage (ETGBD) and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), may be more useful in such patients. ETGBD via a nasobiliary catheter was first reported, and ETGBD via an internal plastic stent was reported a year later \[[@b6-ce-2019-177]\]. This method, through endoscopic retrograde cholangiopancreatography (ERCP), was reported to be effective for gallbladder drainage with relatively high technical and clinical success rates \[[@b7-ce-2019-177]\], and to be an option for patients in whom PTGBD treatment is difficult \[[@b5-ce-2019-177]\]. The next endoscopic method reported was EUS-GBD \[[@b8-ce-2019-177]\], which is a stent placement method under EUS guidance from the antral, duodenal, or jejunal lumen to the gallbladder, and showed higher technical and clinical success rates than expected \[[@b9-ce-2019-177]\]. Currently, EGBD is established as the third choice for the treatment of acute cholecystitis, following LC as the first choice and PTGBD as the second choice, owing to the potential low risk of bleeding of endoscopic methods. Surgical and conservative treatments, including PTGBD or EGBD, for acute cholecystitis in patients with antithrombotic agents will likely become common, as the number of elderly patients with cardiovascular and cerebrovascular diseases is increasing remarkably.

Therefore, the latest guidelines recommended these drainage methods for patients receiving antithrombotic therapy (ATT) or those with a bleeding tendency \[[@b10-ce-2019-177]\]. However, there have been few studies comparing these surgical and percutaneous techniques with EGBD techniques, particularly in terms of bleeding complications, in patients receiving ATT or with a bleeding tendency. To the best of our knowledge, this is the first review on EGBD in patients receiving ATT.

MATERIALS AND METHODS
=====================

From January to February 2019, we searched the PubMed and Google Scholar databases (restricted to articles written in English and published between 1991 and 2018) to retrieve internationally accepted English abstracts of articles on LC and PTGBD in patients receiving ATT or with coagulopathy, and articles about EGBD. The following key words were used for the search: antithrombotic therapy, antiplatelet, anticoagulant, warfarin, clopidogrel, aspirin, bleeding, hemorrhage, endoscopic gallbladder drainage, endoscopic ultrasound-guided gallbladder drainage, endoscopic transpapillary gallbladder drainage, percutaneous transhepatic drainage, cholecystectomy, cholecystostomy, laparoscopic, and cholecystitis. Articles published in peer-reviewed journals as full articles were included in this review. The types of articles included randomized controlled trials (RCTs), prospective studies, and retrospective cohort studies that examined 5 cases or more. Guidelines, review articles, and case series/reports were not included in this analysis. RCTs and prospective studies were of a relatively high evidence level; however, retrospective studies may have had potential selection bias. The quality of each study was assessed depending on the study design, and eligible articles were identified. The full texts of all articles were read by 2 independent reviewers (RS and YA). Complete data were extracted from each study, including the year of publication, type of procedure (LC, PTGBD, ETGBD, or EUS-GBD), study design, sample size, age, sex, and complication rate (including bleeding complications), which were also analyzed in patients receiving ATT or with a bleeding tendency. In addition, the technical and/or clinical success rate and the recurrence rate were analyzed in cases of ETGBD and EUS-GBD. Data were extracted into an Excel spreadsheet for further analysis, including statistical analysis.

Statistical analysis
--------------------

Categorical variables are expressed as proportions and analyzed with Fisher's exact test or the chi-square test, and *p*\<0.05 was considered statistically significant. All data analyses were conducted with SPSS version 24.0 (IBM Co., Armonk, NY, USA).

Definitions
-----------

The bleeding complication rate of each drainage procedure was analyzed in detail. Bleeding complication was defined as the presence of anemia (hemoglobin reduction of 2 g/dL or more), requirement for a blood transfusion, and/or the need for another additional treatment for bleeding such as interventional radiological or surgical therapy. The technical success, clinical success, and recurrence rates were mainly evaluated in ETGBD and EUS-GBD cases. Technical success was defined as successful stent placement in the gallbladder through the cystic duct in ETGBD, and successful stent placement between the stomach or duodenal lumen and the gallbladder in EUS-GBD. Clinical success was defined as the improvement of cholecystitis after the first drainage procedure. Clinical success rate was defined as the proportion of patients with clinical success divided by the proportion of those with technical success. Minor symptoms, such as low-grade fever and mild pain, which were not clinically relevant or conservatively improved, were not included as complications in the present analyses. In this review, early complication was defined as a complication that occurred within 5 days from the procedure, and late complication, a complication that occurred 6 or more days after the procedure. Recurrence rate was defined as the proportion of patients with recurrent acute cholecystitis among those with clinical success, excluding patients who died or underwent stent exchange or elective surgical cholecystectomy. Each rate was calculated considering the non-assessed cases.

Patients with a bleeding tendency were defined as those receiving antiplatelet agents and/or anticoagulants. Patients with moderate or severe liver disease who showed moderate abnormalities of prothrombin time-international normalized ratio (PT-INR) and/or platelet count, including those with end-stage liver disease requiring blood transplantation and those with leukemia and disseminated intravascular coagulation, were also included.

RESULTS
=======

Study collection
----------------

Research article collection and screening were conducted from January 2019 to February 2019. A total of 8 studies on surgical cholecystectomy (mainly LC) \[[@b11-ce-2019-177]-[@b18-ce-2019-177]\], 3 studies on PTGBD \[[@b19-ce-2019-177]-[@b21-ce-2019-177]\], and 1 study on EGBD \[[@b5-ce-2019-177]\] in patients receiving ATT were selected for data extraction and satisfied our inclusion criteria. As only 1 study on EGBD in patients receiving ATT was retrieved through the search method mentioned above, articles were additionally searched using the keywords "ETGBD" and "EUS-GBD". As a result, 27 studies on ETGBD \[[@b6-ce-2019-177],[@b22-ce-2019-177]-[@b47-ce-2019-177]\] and 26 studies on EUS-GBD \[[@b8-ce-2019-177],[@b37-ce-2019-177],[@b40-ce-2019-177],[@b45-ce-2019-177],[@b46-ce-2019-177],[@b48-ce-2019-177]-[@b68-ce-2019-177]\] were newly found. Finally, 28 studies on ETGBD and 26 studies on EUS-GBD were evaluated in this review, which included some cases with bleeding tendency and ATT administration.

Three articles on the EUS-GBD technique were excluded because the procedure was converted from PTGBD, and the accurate therapeutic effects of EUS-GBD could not be evaluated in these cases.

Gallbladder drainage in patients receiving ATT
----------------------------------------------

In the 12 studies that evaluated surgery and gallbladder drainage, patients receiving ATT, including aspirin and/or thienopyridine, were the focus of 3 studies \[[@b12-ce-2019-177],[@b14-ce-2019-177],[@b15-ce-2019-177]\]. Only 1 study evaluated patients receiving anticoagulant therapy with heparin bridging \[[@b11-ce-2019-177]\], 1 study evaluated patients receiving anticoagulant therapy and/or with coagulopathy \[[@b19-ce-2019-177]\], and the other studies \[[@b5-ce-2019-177],[@b13-ce-2019-177],[@b16-ce-2019-177]-[@b18-ce-2019-177],[@b20-ce-2019-177],[@b21-ce-2019-177]\] evaluated patients receiving antiplatelet agents and/or anticoagulants during surgery (LC or OC) or internal drainage (PTGBD or EGBD) without discontinuation of ATT ([Table 1](#t1-ce-2019-177){ref-type="table"}).

Overall, 13.7% (354/2,578) of patients receiving antithrombotic agents underwent LC. There were no significant differences between patients with continued and discontinued antiplatelet therapy (aspirin and/or thienopyridine) in intraoperative blood loss, operative time, conversion rate to open surgery, 30-day morbidity, or bleeding complications requiring blood transfusion \[[@b12-ce-2019-177],[@b14-ce-2019-177],[@b15-ce-2019-177]\]. In some cases of cholecystectomy in patients receiving antiplatelet agents and/or anticoagulants, there were similar tendencies found in LC \[[@b13-ce-2019-177],[@b16-ce-2019-177]\]. On the other hand, 2 studies on cholecystectomy in patients receiving antiplatelet agents and/or anticoagulants reported that anemia was more frequently observed in patients who underwent emergency LC with continuation of ATT \[[@b17-ce-2019-177]\], and that treatment with multiple antiplatelet therapies and anticoagulation therapies was an independent predictor for postoperative bleeding complications \[[@b18-ce-2019-177]\]. Moreover, in a study on LC, it was proven that patients receiving heparin bridging therapy had a significantly higher rate of surgical blood loss than those without anticoagulants \[[@b11-ce-2019-177]\]. Overall, bleeding complications occurred in 6.5% (23/354) of patients with ATT and in 1.2% (26/2,224) of patients without ATT (*p*\<0.001).

With respect to PTGBD, 1 study in patients receiving anticoagulant therapy or with coagulopathy revealed that the cessation of ATT 24 h before the procedure or abnormal coagulation (INR ≥1.5 or platelet count ≤50×10^9^/L) induced major complications related to PTGBD (hemorrhage requiring blood transfusion, sepsis and death directly related to the procedure, and abscess), although they did not occur in patients with normal coagulation, and that 132 patients receiving anticoagulant therapy and/or with coagulopathy had a bleeding complication rate of 1.5% \[[@b19-ce-2019-177]\]. Shibasaki et al. \[[@b20-ce-2019-177]\] reported that in PTGBD followed by elective LC, no bleeding complications were seen in 23 patients receiving ATT. On the other hand, Hamada et al. \[[@b21-ce-2019-177]\] analyzed 34,606 patients who underwent percutaneous transhepatic biliary drainage (PTBD) or PTGBD (23,375 PTBDs and 11,231 PTGBDs), including 1.5% (503/34,606) patients with continued antiplatelet and anticoagulant therapy, both of which were administered on the day of the procedure. The overall rate of severe bleeding complications requiring blood transfusion was 2.3% (PTBD 2.5% and PTGBD 1.6%); however, it was 4% in patients with continued ATT in this study. In addition, continuation of antiplatelet agents was significantly associated with severe bleeding (4.7%, *p*=0.013), whereas no significant difference was observed in the rate of bleeding complications in patients who discontinued antiplatelet agents (*p*=0.517).

There was only 1 study on ETGBD in patients with ATT. In that study, no bleeding complications were seen in any of the 35 cases \[[@b5-ce-2019-177]\].

Present status of EGBD: ETGBD and EUS-GBD
-----------------------------------------

EGBD consists of 2 different methods: transpapillary ETGBD and transmural EUS-GBD. ETGBD requires the ERCP procedure and placement of a plastic stent or nasobiliary catheter into the gallbladder through the duodenal papilla and the cystic duct. EUS-GBD requires EUS guidance, and approaches the gallbladder from the gastric antrum or the duodenum for the drainage procedure. Plastic stents (initially) or metal stents (more recently) are placed between the gallbladder lumen and the gastrointestinal lumen.

There were 28 studies \[[@b5-ce-2019-177],[@b6-ce-2019-177],[@b22-ce-2019-177]-[@b47-ce-2019-177]\] on ETGBD, including 2 RCTs, 3 prospective studies, and 23 retrospective studies ([Table 2](#t2-ce-2019-177){ref-type="table"}). Endoscopic sphincterotomy (EST) in the ETGBD procedure was classified as follows: performed (yes), not performed (no), or on demand. The enrolled patients were 22--95 years old, and 60% (706/1,172) were men. The technical and clinical success rates of ETGBD were 64%--100% and 64%--100%, respectively. The early and late complication rates were 0%--26.5% and 0%--13.7%, respectively. The recurrence rate was 0%--17.6%. Overall, 13.7% (191/1,396) of the patients had some type of bleeding tendency that could be confirmed. The overall technical and clinical success rates were 84% (1,176/1,396) and 92% (1,030/1,119), respectively. Early complications included pancreatitis due to the ERCP procedure, bleeding (especially after EST), choledocholithiasis, cystic duct perforation caused by the guidewire or the cannulation technique, cholangitis, sepsis, migration, and bile leakage. Late complications included pericholecystic fluid collection, cholangitis, duodenal perforation, sepsis, choledocholithiasis, stent migration, stent occlusion, hepatic abscess, and duodenal ulcer, and were treated conservatively. The early and late complication rates were 6.3% (86/1,374) and 5.5% (45/812), respectively. The bleeding complication rate was 0.65% (9/1,374). The overall recurrence rate was 2.2% (23/1,030).

Twenty-six studies \[[@b8-ce-2019-177],[@b37-ce-2019-177],[@b40-ce-2019-177],[@b45-ce-2019-177],[@b46-ce-2019-177],[@b48-ce-2019-177]-[@b68-ce-2019-177]\] on EUS-GBD, including 1 RCT, 4 prospective studies, and 21 retrospective studies, were analyzed ([Table 3](#t3-ce-2019-177){ref-type="table"}). The puncture sites were the duodenal bulb in 55% (334/609), the antrum in 44% (268/609), and the jejunum in 1% (7/609). The enrolled patients were 25--97 years old, and 53% (392/741) were men. The technical and clinical success rates were 85%--100% and 92%--100%, respectively. The early and late complication rates were 0%--28.6% and 0%--15.4%, respectively. The recurrence rate was 0%--8.3%. Eighteen patients had some kind of bleeding tendency. The technical and clinical success rates were 96% (729/758) and 97% (704/723), respectively. Early complications included pneumoperitoneum, peritonitis, perforation, migration, bile fluid collection, bleeding, pancreatic infection, sepsis, and bile leak, whereas the major early complications were pneumoperitoneum and peritonitis. Late complications included stent migration, stent occlusion, abscess, and bleeding. The early and late complication rates were 7.0% (53/758) and 4.4% (33/749), respectively. The bleeding complication rate was 2.1% (16/749). The overall recurrence rate was 3.0% (21/703). These overall results of the reviewed ETGBD and EUS-GBD procedures are shown in [Fig. 1](#f1-ce-2019-177){ref-type="fig"}.

Comparison of ETGBD and EUS-GBD
-------------------------------

The technical and clinical success rates of ETGBD vs. EUS-GBD were 84% (1,176/1,396) vs. 96% (729/758), *p*\<0.001 and 92% (1,030/1,119) vs. 97% (704/723), *p*\<0.001, respectively. These results may suggest that EUS-GBD is easier to perform successfully and is more clinically useful than ETGBD. The early and late complication rates of ETGBD vs. EUS-GBD were 6.3% (86/1,374) vs. 7.0% (53/758), *p*=0.522 and 5.5% (45/812) vs. 4.4% (33/749), *p*=0.352, respectively. The most frequent early complication of ETGBD was pancreatitis, which occurred at a rate of 2.3% (32/1,374) in this study. In EUS-GBD, pneumoperitoneum, peritonitis, and bile leak were the most frequent, and the rate of early complication was 3.8% (29/758). The most frequent late complications of ETGBD and EUS-GBD were migration and occlusion of the drainage tube, which possibly induced recurrent cholecystitis or cholangitis, and the rate was 2.8% (23/812) for ETGBD and 3.0% (23/749) for EUS-GBD. There were no statistically significant differences in the early and late complication rates between ETGBD and EUS-GBD. The recurrence rate was 2.2% (23/1,030) vs. 3.0% (21/703), *p*=0.352. The bleeding complication rate was 0.65% (9/1,374) vs. 2.1% (16/749), *p*=0.005. There were no statistically significant differences in safety and recurrence rate between ETGBD and EUS-GBD; however, the bleeding complication rate was significantly lower with ETGBD.

DISCUSSION
==========

Drainage in patients with acute cholecystitis
---------------------------------------------

In general, the first surgical treatment of choice for patients with acute cholecystitis is LC because of its radicality, safety, minimally invasive nature, and curability compared with OC \[[@b2-ce-2019-177],[@b3-ce-2019-177],[@b10-ce-2019-177]\]. Ingraham et al. reported that the rates of complications, serious complications, and mortality at 30 days after the procedure were 3.1%, 1.4%, and 0.27%, respectively, in an analysis of 58,659 patients who underwent LC \[[@b69-ce-2019-177]\]. Thus, some complications and a higher mortality rate may occur especially in elderly patients and/or in those with multiple severe comorbidities. In such patients with a high risk of emergency surgery, PTGBD has been widely performed as the first choice for internal gallbladder drainage \[[@b4-ce-2019-177]\]. The technical success, clinical success, and complication rates of the PTGBD procedure were 98%, 90% and 3.7%, respectively, indicating a relatively high technical success and reliable effectiveness \[[@b7-ce-2019-177]\].

However, this method has complication and mortality rates as high as 14% and 17.5%, respectively, in poor surgical candidates \[[@b6-ce-2019-177],[@b7-ce-2019-177],[@b70-ce-2019-177]\]. In addition, PTGBD has several problematic features, such as a high recurrence rate (maximum 20%), risk of self-stent removal because of postprocedural pain and discomfort \[[@b6-ce-2019-177],[@b7-ce-2019-177],[@b13-ce-2019-177],[@b70-ce-2019-177]\], and fistula formation after the long-term placement and removal of a catheter \[[@b8-ce-2019-177]\]. Moreover, PTGBD is contraindicated in patients with an anatomically inaccessible gallbladder, ascites, and thrombocytopenia \[[@b5-ce-2019-177]\]. In such patients, EGBD is considered to be more useful as the second-line choice for internal drainage instead of surgery or PTGBD \[[@b5-ce-2019-177],[@b10-ce-2019-177]\].

Some studies reported that EGBD had a similar technical success rate to PTGBD but appeared to be safer and suitable for permanent placement because it has lower complication and recurrence rates than PTGBD \[[@b7-ce-2019-177],[@b45-ce-2019-177],[@b70-ce-2019-177]\]. Accordingly, in our review, ETGBD and EUS-GBD showed relatively high technical and clinical success rates and low complication and recurrence rates. Considering the low recurrence rate of EGBD \[[@b33-ce-2019-177],[@b45-ce-2019-177],[@b61-ce-2019-177]\], long or permanent stent placement in EGBD could be possibly allowed. Therefore, EGBD may be considered as an alternative treatment to LC and PTGBD in various clinical situations.

Current ATT management in the guidelines
----------------------------------------

Antithrombotic agents have been increasingly used for preventing cardiovascular or cerebrovascular diseases in the aging population, and ATT involves the use of agents with 2 different mechanisms: antiplatelet therapy and anticoagulant therapy. Antiplatelet agents, such as aspirin and clopidogrel, are used for the prevention of cardiovascular and cerebrovascular diseases. Anticoagulants, such as warfarin and dabigatran, are used for preventing atrial fibrillation, deep vein thrombosis, and cardiac endoprostheses \[[@b71-ce-2019-177],[@b72-ce-2019-177]\]. Two types of anticoagulants are now increasingly used: direct-acting oral anticoagulants (DOACs) and non-vitamin K antagonist oral anticoagulants (NOACs). The risk of cardiovascular or cerebrovascular events associated with the discontinuation of antithrombotic agents should be fully considered when gallbladder drainage is performed. Recently, the prevention of thromboembolism has been considered to be more important than preventing bleeding complications owing to the severity and mortality of thromboembolism. Therefore, antiplatelet medications, at least aspirin monotherapy, should be continued in patients with a high risk of thromboembolism during therapeutic procedures \[[@b72-ce-2019-177]\].

The management of antithrombotic agents for surgery, PTGBD, and EGBD is indicated in each guideline, considering the thrombosis risk of an individual patient and the procedural risk of bleeding. In patients undergoing elective LC, antiplatelet agents, at least aspirin monotherapy, should be continued if there is a high risk of thromboembolism \[[@b71-ce-2019-177],[@b72-ce-2019-177]\]. Patients receiving warfarin therapy should be switched to heparin bridging for 3--5 days, and those taking DOACs should stop the therapy for 1--2 days or receive heparin bridging therapy before surgery \[[@b72-ce-2019-177]\]. The Society of Interventional Radiology \[[@b73-ce-2019-177]\] recommends the discontinuation of clopidogrel 5 days before PTGBD; however, it is not essentially necessary to discontinue aspirin before the procedure in patients with a high risk of thromboembolism. In addition, it is suggested that the PTINR should be corrected to 1.5.

Guidelines from the Japan Gastroenterological Endoscopy Society \[[@b74-ce-2019-177]\] stipulate that low-bleeding-risk procedures can be performed without discontinuation of all types of antithrombotic agents, although procedures with a high bleeding risk should be carried out with discontinuation of antithrombotic agents. The guidelines also recommend substituting heparin bridging for warfarin or DOACs for these procedures, although the efficacy of bridging therapy is controversial, as Ono et al. reported that heparin bridging therapy increased the bleeding rates to approximately 20% \[[@b74-ce-2019-177]\]. Further accumulation of evidence concerning the management of NOACs is required \[[@b74-ce-2019-177]\].

EST and EUS-GBD are also classified as high-bleedingrisk procedures \[[@b74-ce-2019-177]\], and are allowed without discontinuation of aspirin monotherapy only in patients with a high risk of thromboembolism. However, ETGBD with EST in patients receiving aspirin monotherapy has the potential to increase the rate of bleeding complication. Therefore, ETGBD without EST may be more suitable for patients receiving ATT, as the discontinuation of ATT is not required.

Current status of bleeding complication in ATT
----------------------------------------------

In general, the rate of bleeding complication after LC has been reported to be 0.1%--1.0% \[[@b2-ce-2019-177],[@b71-ce-2019-177]\]. On the other hand, the rate in patients receiving ATT was 0%--25.0% \[[@b11-ce-2019-177]-[@b18-ce-2019-177]\].

Several studies reported that LC in patients receiving ATT might not increase bleeding-related events \[[@b12-ce-2019-177]-[@b17-ce-2019-177]\].

On the contrary, other studies reported that emergency LC has a significant risk of bleeding complications in patients receiving mono- or multiple ATT \[[@b17-ce-2019-177],[@b18-ce-2019-177]\], and in those receiving heparin bridging therapy \[[@b11-ce-2019-177]\]. In our review, 6.5% of the patients receiving ATT who underwent LC (OC in part) experienced bleeding complications, and the rate was significantly higher than that in patients without ATT. Thus, the use of LC in patients receiving ATT remains controversial.

With respect to PTGBD, 2 studies concluded that there was no significant increase in bleeding complications in patients receiving ATT and/or with coagulopathy \[[@b19-ce-2019-177],[@b20-ce-2019-177]\]. On the other hand, another study concluded that continuation of antiplatelet agents could increase the risk of severe bleeding after PTBD \[[@b21-ce-2019-177]\]. The use of PTGBD in patients receiving ATT also remains controversial, as this technique may pose a bleeding risk in patients with acute cholecystitis receiving ATT.

In our review, the bleeding complication rate of ETGBD was low (0.65%) in 1,374 patients, and only 1 patient (0.5%) experienced bleeding after the procedure among 191 patients receiving ATT or with some type of coagulopathy. EST was considered a main cause of bleeding complications after ERCP \[[@b74-ce-2019-177]\], as 151 patients who underwent ETGBD without EST did not show any bleeding complications. In EUS-GBD, the rate of bleeding complication was 2.1%. Among patients receiving ATT or with coagulopathy, bleeding complication was confirmed in 2.4% (18 of 758 patients); in 2 patients, bleeding might have been caused by ATT. Some studies reported that EUS-GBD could be safer to perform than PTGBD in patients with anticoagulant therapy because the gastrointestinal tract is less vascular than the liver \[[@b13-ce-2019-177],[@b58-ce-2019-177]\]. However, on the basis of our review, bleeding complications might occur with a certain probability, although they are rarely severe and fatal \[[@b63-ce-2019-177]\].

Future perspectives in EGBD for ATT
-----------------------------------

ETGBD may be safer than EUS-GBD or PTGBD in patients receiving ATT or with coagulopathy, because this procedure does not require needle puncture or fistula dilation \[[@b51-ce-2019-177]\]. However, the technical success rate of ETGBD is lower than that of EUS-GBD. ETGBD is technically challenging, especially the cannulation procedure \[[@b40-ce-2019-177],[@b70-ce-2019-177]\], and requires an expert endoscopist. More experience with wire manipulation might improve the technical success rates \[[@b29-ce-2019-177]\]. In addition, special methods combined with cholangioscopy have been proposed, and their superiority in detecting the orifice of the cystic duct in the common bile duct has been proven \[[@b38-ce-2019-177]\]. Improvements in the technique and modality could further increase the success rate.

From the result of the present review, we conclude that ETGBD without EST may be an ideal treatment for patients receiving ATT from the viewpoint of preventing bleeding complications. However, patients undergoing ETGBD without EST may have a higher risk of other common complications, such as pancreatitis and cholangitis, different from EUS-GBD. Lee et al. \[[@b33-ce-2019-177]\] emphasized the risk of post-EST bleeding and that EST should not be necessarily required in all cases. Thus, EST should be avoided whenever possible to reduce the risk of severe complications. Endoscopic papillary balloon dilation (EPBD) may solve this dilemma, because this technique is classified as a low-bleeding-risk procedure based on its lower risk of bleeding complications than EST \[[@b74-ce-2019-177]\]. In addition, EPBD prevents complications such as pancreatitis or cholangitis resulting from the obstruction of the papillary orifice \[[@b33-ce-2019-177]\]. Therefore, ETGBD with on-demand EPBD should be alternatively performed in patients with acute cholecystitis with coagulopathy, cirrhotic liver, and ATT. EUS-GBD may be the second ideal option for drainage treatment when ETGBD has failed or is not adopted. The results of the present review are summarized and compared with the guideline recommendations in [Table 4](#t4-ce-2019-177){ref-type="table"}.

This review has some limitations. First, the sample size is relatively small for evaluating the incidence and risk of relatively rare bleeding complications. In future studies, a much higher number of samples may be possible. Second, as the number of patients receiving antithrombotic agents may also be small, the comparisons of the different drainage methods are partly indirect. Third, the baseline characteristics of patients with ATT and coagulopathy that possibly influenced the review results were not fully known. However, we believe that the scale of their influence did not cause a serious misunderstanding in the review process.

CONCLUSIONS
===========

The use of LC and PTGBD in patients with acute cholecystitis receiving ATT or with coagulopathy remains controversial. Therefore, ETGBD without EST should be considered as the first-choice treatment in patients with acute cholecystitis who cannot undergo cholecystectomy because of the use of ATT.

In addition, EUS-GBD may also be a potential alternative treatment in patients who are not suitable for PTGBD and ETGBD. To clarify the efficacy and feasibility of EGBD in patients receiving ATT, further studies, especially randomized controlled prospective studies, are needed.
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###### 

Patient Characteristics and Complication Rates of Gallbladder Drainage Procedures in Patients Receiving Antithrombotic Therapy or with Coagulopathy

  Study                                            Therapeutic method for acute cholecystitis   Study Design    Patients with bleeding tendency (all patients)   Age    Male, % (*n*)   Antithrombotics or coagulopathy      Complication rate, % (*n*)   Bleeding complication rate, % (*n*)   Increase in bleeding related events   
  ------------------------------------------------ -------------------------------------------- --------------- ------------------------------------------------ ------ --------------- ------------------------------------ ---------------------------- ------------------------------------- ------------------------------------- -----
  Ercan et al. (2010) \[[@b11-ce-2019-177]\]       LC                                           Retrospective   44 (1,465)                                       55.4   32 (14)         Anticoagulant                        N/A                          25 (11)                               2.9 (32)                              Yes
  Ono et al. (2013) \[[@b12-ce-2019-177]\]         LC                                           Retrospective   29 (270)                                         70.3   69 (20)         Antiplatelet (Aspirin)               N/A                          0 (0)                                 0.3 (1)                               No
  Noda et al. (2014) \[[@b13-ce-2019-177]\]        LC                                           Retrospective   21 (183)                                         71.9   62 (13)         Antiplatelets and/or anticoagulant   14.3 (3)                     0 (0)                                 0.5 (1)                               No
  Anderson et al. (2014) \[[@b14-ce-2019-177]\]    LC                                           Retrospective   36 (72)                                          68.8   53 (19)         Antiplatelet (Clopidogrel)           22.2 (8)                     0 (0)                                 1.4 (1)                               No
  Joseph et al. (2015) \[[@b15-ce-2019-177]\]      LC                                           Retrospective   56 (112)                                         65.9   54 (30)         Antiplatelets                        8.9 (5)                      1.8 (1)                               1.8 (2)                               No
  Akahoshi et al. (2017) \[[@b16-ce-2019-177]\]    OC/LC                                        Retrospective   13 (113)                                         64.5   92 (12)         Antiplatelets and/or anticoagulant   7.7 (1)                      0 (0)                                 0 (0)                                 No
  Yun et al. (2017) \[[@b17-ce-2019-177]\]         LC                                           Retrospective   22 (67)                                          72.5   50 (11)         Antiplatelets and/or anticoagulant   18.2 (4)                     13.6 (3)                              4.5 (3)                               Yes
  Kawamoto et al. (2018) \[[@b18-ce-2019-177]\]    OC/LC                                        Retrospective   133 (296)                                        76     68 (91)         Antiplatelets and/or anticoagulant   18.8 (25)                    6.0 (8)                               3.0 (9)                               Yes
  Dewhurst et al. (2012) \[[@b19-ce-2019-177]\]    PTGBD                                        Retrospective   132 (242)                                        N/A    N/A             Anticoagulant and/or coagulopathy    6.0 (8)                      1.5 (2)                               1.7 (4)                               No
  Shibasaki et al. (2014) \[[@b20-ce-2019-177]\]   PTGBD                                        Retrospective   23 (87)                                          71     70 (16)         Antiplatelets and/or anticoagulant   N/A                          0 (0)                                 0 (0)                                 No
  Hamada et al. (2015) \[[@b21-ce-2019-177]\]      PTGBD/PTBD                                   Retrospective   503 (34,606)                                     N/A    N/A             Antiplatelets and/or anticoagulant   N/A                          4.0 (20)                              2.3 (780)                             Yes
  Itoi et al. (2008) \[[@b5-ce-2019-177]\]         ETGBD                                        Retrospective   35 (43)                                          N/A    N/A             Antiplatelets and/or anticoagulant   0 (0)                        0 (0)                                 0 (0)                                 No

ETGBD, endoscopic transpapillary gallbladder drainage; LC, laparoscopic cholecystectomy; N/A, no assessment; OC, open cholecystectomy; PTBD, percutaneous transhepatic biliary drainage; PTGBD, percutaneous transhepatic gallbladder drainage.

###### 

Success and Complication Rates of Endoscopic Transpapillary Gallbladder Drainage

  Study                                            Study Design    Patient number   Age    Male, % (*n*)   Technical success rate, % (*n*)   Clinical success rate, % (*n*)   Early complication rate, % (*n*)   Late complication rate, % (*n*)   EST   Bleeding tendency, *n*   Bleeding complications, *n*   Recurrence rate, % (*n*)
  ------------------------------------------------ --------------- ---------------- ------ --------------- --------------------------------- -------------------------------- ---------------------------------- --------------------------------- ----- ------------------------ ----------------------------- --------------------------
  Tamada et al. (1991) \[[@b6-ce-2019-177]\]       Retrospective   14               65     64 (9)          100 (14)                          64 (9)                           0 (0)                              0 (0)                             Yes   N/A                      0                             N/A
  Feretis et al. (1993) \[[@b22-ce-2019-177]\]     Retrospective   18               67     44 (8)          89 (16)                           100 (16)                         0 (0)                              0 (0)                             Yes   N/A                      0                             0 (0)
  Johlin et al. (1993) \[[@b23-ce-2019-177]\]      Retrospective   7                59     29 (2)          100 (7)                           71 (5)                           0 (0)                              0 (0)                             OD    N/A                      0                             0 (0)
  Nakatsu et al. (1997) \[[@b24-ce-2019-177]\]     Retrospective   21               66     29 (6)          81 (17)                           100 (17)                         0 (0)                              0 (0)                             No    2                        0                             0 (0)
  Shrestha et al. (1999) \[[@b25-ce-2019-177]\]    Prospective     13               44     69 (9)          100 (13)                          100 (13)                         0 (0)                              7.7 (1)                           No    13                       0                             7.7 (1)
  Conway et al. (2005) \[[@b26-ce-2019-177]\]      Retrospective   29               46.9   N/A             90 (26)                           100 (26)                         6.9 (2)                            3.4 (1)                           No    29                       0                             3.8 (1)
  Toyota et al. (2006) \[[@b27-ce-2019-177]\]      Retrospective   22               52.5   45 (10)         82 (18)                           100 (18)                         N/A                                N/A                               No    N/A                      N/A                           N/A
  Schlenker et al. (2006) \[[@b28-ce-2019-177]\]   Retrospective   23               48.5   78 (18)         100 (23)                          100 (23)                         0 (0)                              8.7 (2)                           No    23                       0                             8.7 (2)
  Kjaer et al. (2007) \[[@b29-ce-2019-177]\]       Retrospective   34               57.5   38 (13)         71 (24)                           88 (21)                          8.8 (3)                            2.9 (1)                           OD    N/A                      0                             0 (0)
  Itoi et al. (2008) \[[@b5-ce-2019-177]\]         Retrospective   43               72     38 (25)         84 (36)                           97 (35)                          0 (0)                              N/A                               No    35                       0                             N/A
  Ogawa et al. (2008) \[[@b30-ce-2019-177]\]       Retrospective   11               68.7   73 (8)          64 (7)                            100 (7)                          0 (0)                              N/A                               N/A   N/A                      0                             N/A
  Pannala et al. (2008) \[[@b31-ce-2019-177]\]     Retrospective   51               62     67 (34)         100 (51)                          100 (51)                         7.8 (4)                            13.7 (7)                          N/A   N/A                      2                             0 (0)
  Mutignani et al. (2009) \[[@b32-ce-2019-177]\]   Retrospective   35               64.9   66 (23)         83 (29)                           83 (24)                          5.7 (2)                            2.9 (1)                           Yes   7                        0                             16.7 (4)
  Lee et al. (2011) \[[@b33-ce-2019-177]\]         Prospective     29               74     48 (14)         79 (23)                           100 (23)                         10.3 (3)                           10.3 (3)                          OD    1                        0                             0 (0)
  Maekawa et al. (2013) \[[@b34-ce-2019-177]\]     Retrospective   46               79.7   54 (25)         80 (37)                           100 (37)                         0 (0)                              4.3 (2)                           OD    N/A                      0                             2.7 (1)
  Yane et al. (2015) \[[@b35-ce-2019-177]\]        Prospective     27               65.6   44 (12)         78 (21)                           95 (20)                          14.8 (4)                           N/A                               OD    7                        0                             N/A
  Itoi et al. (2015) \[[@b36-ce-2019-177]\]        RCT             73               68.4   64 (47)         89 (65)                           92 (60)                          4.1 (3)                            N/A                               OD    21                       1                             N/A
  Kedia et al. (2015) \[[@b37-ce-2019-177]\]       Retrospective   24               N/A    N/A             100 (24)                          N/A                              12.5 (3)                           0 (0)                             Yes   N/A                      2                             N/A
  McCarthy et al. (2015) \[[@b38-ce-2019-177]\]    Retrospective   29               70     59 (17)         76 (22)                           100 (22)                         0 (0)                              3.4 (1)                           OD    N/A                      0                             0 (0)
  Tujios et al. (2015) \[[@b39-ce-2019-177]\]      Retrospective   34               52     53 (18)         94 (32)                           88 (28)                          26.5 (9)                           8.8 (3)                           OD    34                       0                             0 (0)
  Widmer et al. (2015) \[[@b40-ce-2019-177]\]      Retrospective   128              N/A    N/A             91 (117)                          100 (117)                        2.3 (3)                            1.6 (2)                           Yes   N/A                      1                             N/A
  Hatanaka et al. (2016) \[[@b41-ce-2019-177]\]    Retrospective   22               74.5   59 (13)         77 (17)                           100 (17)                         0 (0)                              0(0)                              OD    N/A                      0                             17.6 (3)
  Inoue et al. (2016) \[[@b42-ce-2019-177]\]       Retrospective   35               74.5   43 (15)         83 (29)                           100 (29)                         2.9 (1)                            8.6 (3)                           OD    N/A                      0                             0 (0)
  Yang et al. (2016) \[[@b43-ce-2019-177]\]        RCT             35               57.5   51 (18)         86 (30)                           90 (27)                          14.3 (5)                           N/A                               Yes   N/A                      0                             N/A
  Itoi et al. (2017) \[[@b44-ce-2019-177]\]        Retrospective   330              N/A    64 (212)        70 (232)                          89 (207)                         8.2 (27)                           N/A                               N/A   N/A                      2                             N/A
  Siddiqui et al. (2019) \[[@b45-ce-2019-177]\]    Retrospective   124              60.3   68 (84)         88 (109)                          91 (99)                          4.0 (5)                            4.8 (6)                           Yes   N/A                      1                             4.0 (4)
  Oh et al. (2019) \[[@b46-ce-2019-177]\]          Retrospective   96               65.6   69 (66)         83 (80)                           99 (79)                          8.3 (8)                            12.5 (12)                         Yes   6                        0                             8.9 (7)
  Iino et al. (2018) \[[@b47-ce-2019-177]\]        Retrospective   43               N/A    N/A             77 (33)                           N/A                              9.3 (4)                            N/A                               No    13                       0                             N/A

EST, endoscopic sphincterotomy; N/A, no assessment; OD, on demand; RCT, randomized controlled trial.

###### 

Success and Complication Rates of Endoscopic Ultrasound-Guided Gallbladder Drainage

  Study                                                      Study Design    Patient number   Age    Male, % (*n*)   Technical success rate, % (*n*)   Clinical success rate, % (*n*)   Early complication rate, % (*n*)   Late complication rate, % (*n*)   Bleeding tendency, *n*   Bleeding complication, *n*   Recurrence rate, % (*n*)
  ---------------------------------------------------------- --------------- ---------------- ------ --------------- --------------------------------- -------------------------------- ---------------------------------- --------------------------------- ------------------------ ---------------------------- --------------------------
  Lee et al. (2007) \[[@b48-ce-2019-177]\]                   Prospective     9                64     56 (5)          100 (9)                           100 (9)                          11.1 (1)                           N/A                               N/A                      0                            N/A
  Song et al. (2010) \[[@b49-ce-2019-177]\]                  Prospective     8                72     38 (3)          100 (8)                           100 (8)                          12.5 (1)                           12.5 (1)                          N/A                      0                            0 (0)
  Jang et al. (2011) \[[@b50-ce-2019-177]\]                  Prospective     15               74     40 (6)          100 (15)                          100 (15)                         13.3 (2)                           0 (0)                             N/A                      0                            0 (0)
  Itoi et al. (2012) \[[@b51-ce-2019-177]\]                  Retrospective   5                72.6   60 (3)          100 (5)                           100 (5)                          0 (0)                              0 (0)                             N/A                      0                            0 (0)
  Jang et al. (2012) \[[@b8-ce-2019-177]\]                   RCT             30               62     57 (17)         97 (29)                           100 (29)                         6.7 (2)                            0 (0)                             N/A                      0                            0 (0)
  de la Serna-Higuera et al. (2013) \[[@b52-ce-2019-177]\]   Retrospective   13               79.9   62 (8)          85 (11)                           100 (11)                         7.7 (1)                            0 (0)                             N/A                      1                            0 (0)
  Choi et al. (2014) \[[@b53-ce-2019-177]\]                  Retrospective   63               68     52 (33)         98 (62)                           100 (62)                         4.8 (3)                            3.2 (2)                           N/A                      0                            3.2 (2)
  Widmer et al. (2015) \[[@b40-ce-2019-177]\]                Retrospective   11               N/A    N/A             100 (11)                          100 (11)                         0 (0)                              9.1 (1)                           N/A                      0                            N/A
  Irani et al. (2015) \[[@b54-ce-2019-177]\]                 Retrospective   15               74     53 (8)          93 (14)                           100 (14)                         0 (0)                              0 (0)                             4                        0                            0 (0)
  Kedia et al. (2015) \[[@b37-ce-2019-177]\]                 Retrospective   6                N/A    N/A             100 (6)                           N/A                              16.7 (1)                           0 (0)                             N/A                      0                            N/A
  Imai et al. (2016) \[[@b55-ce-2019-177]\]                  Retrospective   12               67.3   66 (8)          100 (12)                          92 (11)                          16.7 (2)                           0 (0)                             N/A                      0                            0 (0)
  Takagi et al. (2016) \[[@b56-ce-2019-177]\]                Retrospective   16               73.7   75 (12)         100 (16)                          100 (16)                         6.3 (1)                            0 (0)                             N/A                      0                            0 (0)
  Tyberg et al. (2018) \[[@b57-ce-2019-177]\]                Retrospective   42               74     57 (24)         95 (40)                           100 (40)                         11.9 (5)                           7.1 (3)                           N/A                      1                            7.5 (3)
  Ge et al. (2016) \[[@b58-ce-2019-177]\]                    Retrospective   7                73.2   43 (3)          100 (7)                           100 (7)                          0 (0)                              0 (0)                             N/A                      0                            0 (0)
  Kahaleh et al. (2016) \[[@b59-ce-2019-177]\]               Retrospective   35               81     46 (16)         91 (32)                           97 (31)                          11.4 (4)                           11.4 (4)                          N/A                      2                            6.5 (2)
  Walter et al. (2016) \[[@b60-ce-2019-177]\]                Retrospective   30               85     37 (11)         90 (27)                           96 (26)                          6.7 (2)                            6.7 (2)                           N/A                      0                            7.7 (2)
  Choi et al. (2017) \[[@b61-ce-2019-177]\]                  Prospective     14               78     43 (6)          86 (12)                           92 (11)                          28.6 (4)                           0 (0)                             N/A                      0                            0 (0)
  Kamata et al. (2017) \[[@b62-ce-2019-177]\]                Retrospective   12               76.3   75 (9)          100 (12)                          100 (12)                         0 (0)                              0 (0)                             N/A                      0                            3.3 (1)
  Manta et al. (2017) \[[@b63-ce-2019-177]\]                 Retrospective   16               84.8   56 (9)          100 (16)                          94 (15)                          6.3 (1)                            12.5 (2)                          N/A                      2                            0 (0)
  Dollhopf et al. (2017) \[[@b64-ce-2019-177]\]              Retrospective   75               75     48 (36)         99 (74)                           95 (70)                          4.0 (3)                            4.0 (3)                           N/A                      1                            4.3 (3)
  Teoh et al. (2017) \[[@b65-ce-2019-177]\]                  Retrospective   59               82.7   51 (30)         97 (57)                           93 (53)                          5.1 (3)                            8.5 (5)                           N/A                      2                            0 (0)
  Irani et al. (2017) \[[@b66-ce-2019-177]\]                 Retrospective   45               65     64 (29)         98 (44)                           98 (43)                          6.7 (3)                            4.4 (2)                           4                        2                            7.0 (3)
  Cho et al. (2019) \[[@b67-ce-2019-177]\]                   Retrospective   22               74.5   68 (15)         96 (21)                           100 (21)                         0 (0)                              4.5 (1)                           3                        0                            0 (0)
  Ahmed et al. (2018) \[[@b68-ce-2019-177]\]                 Retrospective   13               74.9   77 (10)         100 (13)                          92 (12)                          7.7 (1)                            15.4 (2)                          N/A                      0                            8.3 (1)
  Siddiqui et al. (2019) \[[@b45-ce-2019-177]\]              Retrospective   102              72.4   57 (58)         96 (94)                           96 (90)                          8.8 (9)                            2.0 (2)                           N/A                      5                            1.1 (1)
  Oh et al. (2019) \[[@b46-ce-2019-177]\]                    Retrospective   83               68.4   40 (33)         99 (82)                           100 (82)                         4.8 (4)                            3.6 (3)                           7                        0                            3.7 (3)

N/A, no assessment; RCT, randomized controlled trial.

###### 

Assessment of the Review Results Regarding a Comparison with the Recommendation of the Guideline in Patients with Antithrombotic Therapy including Bleeding Tendency

                                                                                                   Guidelines                                                                                                                          Our review                                                Assessment
  ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------
  Surgery (mainly LC)                                                                              1\) Discontinuation of ATT is recommended.                                                                                          1\) Surgery under continuation of ATT is controversial.   Need further discussion
  2\) Continuation of aspirin monotherapy is acceptable.                                           2\) Bleeding complication rate is 6.5% in patients receiving ATT.                                                                                                                             
  PTGBD                                                                                            1\) Discontinuation of ATT is recommended.                                                                                          1\) PTGBD under continuation of ATT is controversial.     Need further discussion
  2\) Continuation of aspirin monotherapy is acceptable.                                                                                                                                                                                                                                         
  ETGBD                                                                                            1\) With EST: discontinuation of ATT is recommended.                                                                                1\) Few evidence                                          Recommendation
  2\) Without EST: continuation of all type ATT is recommended.                                    2\) Bleeding complication rate is 0.65% in all patients, 0% in all patients without EST, 0.5% in patients with bleeding tendency.                                                             
  EUS-GBD                                                                                          1\) Discontinuation of ATT is recommended.                                                                                          1\) Few evidence                                          Need further discussion
  2\) Bleeding complication rate 2.1% in all patients, 11.1% in patients with bleeding tendency.                                                                                                                                                                                                 

ATT, antithrombotic therapy; EST, endoscopic sphincterotomy; ETGBD, endoscopic transpapillary gallbladder drainage; EUS-GBD, endoscopic ultrasound-guided gallbladder drainage; LC, laparoscopic cholecystectomy; PTGBD, percutaneous transhepatic gallbladder drainage.
